Samsung Medical Center
CAR T-cell therapy in the Republic of Korea typically costs from AUD $537,027 to AUD $718,361. Final prices depend on the specific drug used, such as Kymriah, and the hospital tier. In Australia, this treatment averages AUD $676,515. Australians can save approximately 21% by travelling to South Korea. Costs generally include 20 to 21 days of hospitalisation for safety monitoring.
Bookimed Expert Insight: South Korea offers a significant price advantage for private patients compared to other advanced nations. Major centres like Samsung Medical Center are recognised as some of the world's best hospitals by Newsweek. They use sophisticated facilities and AI technology to monitor patient recovery. This level of infrastructure is often bundled into the treatment cost, providing high value for complex interventions.
| Republic of Korea | Thailand | Turkey | |
| CAR T-cell therapy | from AUD $537,027 | from AUD $348,719 | from AUD $209,231 |
No hidden fees – just official clinic prices. Pay at the clinic for CAR T-cell therapy upon arrival and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in CAR T-cell therapy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your CAR T-cell therapy journey.
Common side effects of CAR T-cell therapy in Korea include Cytokine Release Syndrome (CRS) and neurological toxicity (ICANS). Specialists at centres like Seoul's Samsung Medical Center manage these effects during a mandatory 10-day monitoring period. This monitoring helps protect patient safety and supports long-term recovery.
Bookimed Expert Insight: Data shows Korean oncology centres focus heavily on immediate safety. They require patients to stay within 30 minutes of the hospital for 30 days. Facilities like Samsung Medical Center provide integrated ICU access. They also keep tocilizumab immediately available to neutralise severe immune reactions.
Patient Consensus: Patients in Korea find that intensive 10-day hospital monitoring helps catch early symptoms quickly. These symptoms include fever and confusion. Most people report that brain fog and fatigue can last for several months. This happens after the initial hospital stay.
Republic of Korea clinics provide CAR T-cell therapy for specific relapsed or refractory blood cancers. Approved treatments target B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, and multiple myeloma. Specialist centres like Samsung Medical Center use MFDS-approved protocols including Kymriah and domestically developed therapies.
Bookimed Expert Insight: While most international patients seek Kymriah, Korea’s domestic drug Rimqarto shows significant promise for lymphoma. Samsung Medical Center’s partnership with the Mayo Clinic means these local protocols meet global clinical standards. This dual-track availability provides more options. It benefits patients who do not respond to standard CAR T drugs.
Patient Consensus: Patients find the process for blood cancers very established in Seoul. They recommend sticking to MFDS-approved therapies and major medical centres. Trials for solid tumours are interesting but still seen as experimental by most families.
South Korea offers Kymriah, Yescarta, and Carvykti for haematologic malignancies like leukaemia and multiple myeloma. Clinically approved domestic options include Rimqarto, developed by Curocell. Specialists at Samsung Medical Centre administered the first treatments. Costs range from $385,000 to $515,000.
Bookimed Expert Insight: Samsung Medical Centre serves over 2 million outpatients annually. It also houses one of Asia’s largest cancer centres. Its partnership with the Mayo Clinic means CAR T-cell protocols meet rigorous international standards. Choosing a high-volume centre like this is vital. It helps manage the intensive care required after infusion.
Patient Consensus: Patients find that accessing Kymriah in Korea is more affordable than in Australia. This is due to local insurance coverage. Many travellers look for clinical trials in Seoul. They seek newer therapies that are not yet available commercially.
South Korea offers numerous clinical trials for CAR T-cell therapy. These focus on blood cancers and solid tumours. Institutions such as Samsung Medical Center and Seoul National University Hospital lead these studies. Recent local approvals like Anbal-cel provide additional options alongside global therapies like Kymriah.
Bookimed Expert Insight: Samsung Medical Center serves over 2 million outpatients annually. It also maintains a direct partnership with the Mayo Clinic. This connection often gives patients faster access to international trial protocols. It also offers collaborative expertise for complex cases. It is a major differentiator for those seeking high-volume clinical experience in Seoul.
Patient Consensus: Korea's Regenerative Medicine Law allows access to cell therapies for severe conditions outside traditional trials. Patients suggest that during consultations, clinics should distinguish CAR T-cell therapy from standard stem cell treatments.
South Korea National Health Insurance (NHI) covers CAR T-cell therapy for eligible residents with specific blood cancers. Since April 2022, Kymriah is reimbursed for third-line treatment of diffuse large B-cell lymphoma. It also covers paediatric acute lymphoblastic leukaemia in the third line. Coverage significantly reduces costs for those enrolled in the national scheme.
Bookimed Expert Insight: While NHI offers massive savings, these benefits only apply to residents. International patients usually pay full price, which ranges from $385,000 to $515,000. Samsung Medical Center, Asia's largest cancer centre, manages these complex cases regularly.
Patient Consensus: Korea provides high coverage for cancer through NHI. Foreigners without residency should prepare for costs 20 times higher than local residents. Major hospitals in Seoul offer the most reliable guidance on insurance eligibility.
CAR T-cell therapy in Korea faces several challenges. These include high costs (from $385,000 to $515,000). Other challenges are limited access outside Seoul and complex logistics for cell manufacturing. Patients must also manage severe clinical toxicities like Cytokine Release Syndrome (CRS). They need specialised intensive care facilities for this.
Bookimed Expert Insight: While costs are high, Bookimed data shows Samsung Medical Centre manages over 2 million outpatients annually. They partner with the Mayo Clinic and use integrated digital imaging systems. Together, these help manage complex CAR T-cell cases. Patients should confirm specific product availability as Korean approval varies by cancer type.
Patient Consensus: Success rates for severe relapsed cases can sit around 40% in Korea. Recovery requires strict isolation and 4+ months of precautions like eating only cooked food. Patients frequently have low blood counts and weakened immunity. This can last for months after treatment.